2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
7
Breast Neoplasms
5
Ovarian Neoplasms
4
Pancreatic Neoplasms
3
Colorectal Neoplasms, Hereditary Nonpolyposis
3
Triple Negative Breast Neoplasms
2
Neoplastic Syndromes, Hereditary
2
Hereditary Breast and Ovarian Cancer Syndrome
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Urogenital Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Fanconi Anemia, Complementation Group D1
1
Digestive System Neoplasms
1
Cytopenia
1
Congenital Bone Marrow Failure Syndromes
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Intraductal, Noninfiltrating
1
Cancer Risk Syndrome
1
Interventions
pembrolizumab
300
Nivolumab
273
Ipilimumab
250
aldesleukin
137
Cyclophosphamide
136
Interleukin-2
105
trametinib
82
dabrafenib
76
Temozolomide
75
Dacarbazine
74
Vemurafenib
71
fludarabine
68
fludarabine phosphate
62
Biopsy
49
binimetinib
47
sargramostim
44
Radiosurgery
44
Bevacizumab
43
Paclitaxel
42
encorafenib
40
incomplete Freund's adjuvant
39
atezolizumab
38
Radiotherapy
37
Specimen Handling
36
Cisplatin
36
CTLA-4 Antigen
36
Magnetic Resonance Spectroscopy
35
Carboplatin
35
cobimetinib
34
Introns
33
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Genetic Counseling
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled